Unique Organics (530997)

Score breakdown: P/E: 3/3 · ROCE: 2/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• High ROE of 21.95% and ROCE of 50.11% indicate strong capital efficiency
• Debt/Equity not reported, suggesting a no-leverage or clean balance sheet
• P/E of 8.12 and P/B of 2.02 offer a margin of safety if earnings hold
• Latest quarter remains profitable with ₹2 Cr net profit on ₹17 Cr sales
• Price is 20% below the 52-week high, providing room for recovery

Concerns

• Sales growth of -71.24% signals a major erosion in business scale
• Piotroski F-Score of 3/9 points to weak fundamental health
• Zero dividend yield means no income buffer for shareholders
• Promoter holding is undisclosed, a red flag for a micro-cap

AI Analysis

Let's examine Unique Organics through a value investor's lens. A P/E of 8.12 and a 21.95% ROE initially look tempting, and a ROCE over 50% suggests efficient capital use. But Graham warned us to dig beneath the surface. Sales collapsed by 71.24%, yet profit fell only 34.77% — that means margins expanded dramatically. In the latest quarter, ₹17 Cr of sales produced ₹2 Cr net profit, implying a ~12% margin. I ask myself: is this a fundamentally improved business or a one-off lucky quarter? The Piotroski F-Score of 3/9 screams financial stress, and the absence of any dividend means I rely solely on price appreciation. With no promoter holding data and a market cap of just ₹61 Cr, this is a thinly traded micro-cap. I also see book value of ₹50.52, so I'm paying ₹101.97 — roughly 2 times tangible assets — for a commodity-linked agricultural business with no clear moat. The 52-week range of ₹65 to ₹127.50 shows how volatile this stock can be. Could it be a turnaround? Perhaps. But as Buffett says, 'Turnarounds seldom turn.' I'd need to understand why sales fell so sharply and whether the current earnings are repeatable. For now, this is a possible cyclical or event-driven play, not a predictable compounding machine. I'd wait for more stable revenue and better financial health signals before committing capital.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer